Clinical Trial Success Uncertainty: The ultimate approval and commercial viability of Kazia's lead drug candidate, paxalisib, depends entirely on the successful outcome of ongoing and future clinical trials for efficacy and safety. Negative results would severely impact the company's prospects.

Regulatory Approval Risk: Even with positive clinical data, securing marketing authorization from regulatory bodies like the FDA or EMA is not guaranteed, involves complex processes, and can face unexpected delays or rejections.

Capital and Funding Requirements: Kazia is a clinical-stage company that consumes significant capital for research and development activities. The inability to secure additional funding when needed could force delays or abandonment of development programs.